Dr. Soha Abdelbaky is a highly skilled and experienced medical oncologist specializing in the treatment of various types of cancer, including breast cancer, gynecological tumors, lung cancer, gastrointestinal cancer, urological tumors, and hematological malignancies such as leukemia, lymphoma, and multiple myeloma.
With a strong background in oncology, Dr. Soha has dedicated her career to providing comprehensive and personalized care to patients facing cancer diagnoses. She is known for her expertise in the management of breast cancer, employing the latest advancements in targeted therapies, immunotherapies, and hormone therapies to optimize treatment outcomes.
In addition to breast cancer, Dr. Soha has extensive experience in managing gynecological tumors, including ovarian, cervical, and uterine cancers. She is adept at creating individualized treatment plans that consider the unique characteristics of each patient's tumor and their overall health status.
Furthermore, Dr. Soha has in-depth knowledge of lung cancer, gastrointestinal cancer (such as colorectal cancer, pancreatic cancer, and gastric cancer), and urological tumors (such as bladder cancer, kidney cancer, and prostate cancer). She stays abreast of the latest research and treatment options in these areas to offer the most effective and cutting-edge therapies to her patients.
Dr. Soha’s expertise extends to hematological malignancies, including leukemia, lymphoma, and multiple myeloma. She is skilled in diagnosing and managing these complex diseases, utilizing a multidisciplinary approach that may involve chemotherapy, targeted therapies, immunotherapies, stem cell transplantation, and supportive care.
Throughout her career, Dr. Soha Abdelbaky has many national and international research and publications, namely,
- Low Expression and Promoter Hypermethylation of the Tumour Suppressor SLIT2, are Associated with Adverse Patient Outcomes in Diffuse Large B Cell Lymphoma. Pathol Oncol Res. 2019.
- Chemotherapy and targeted therapy for breast cancer patients with hepatitis C virus infection. Breast Cancer.
- Axillary Irradiation in Breast Cancer; Does Meticulous Contouring Make a Differance?. Tumori Journal BGICS Abstract Book. 2018.
- Effect of chemotherapy on the nutritional status of Egyptian patients with breast cancer. Research In Oncology; December 2016.
- Second-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): chemotherapy at NEMROCK. December 2016
- NEMROCK center experience In: European Society Of Medical Oncology. 2017. May 4-6; Belgium, Abstract nr 8p.
- VMAT in locally advanced lung cancer; does it add benefit? Radiotherapy and Oncology
- Pathological Complete Response in Obese Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer. Tumori Journal BGICS Abstract Book.
- Children Exposed to Treatments in Utero in Pregnant Patients with Breast Cancer: Research in Oncology, 2018.
- Adjuvant chemotherapy for elderly (>65 years) breast cancer patients: a retrospective study. Cancer Biology 2018.
- Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients. Asian Pac J Cancer Prev. 2019
- Clinico-Epidemiological Study of Elderly Breast Cancer in a Developing Country: Egypt. Journal of Cancer Treatment and Research 2019.
- Association of serum level of vitamin D and VDR polymorphism Fok1 with the risk or survival of pancreatic cancer in Egyptian population. April 2019 Indian Journal of Cancer.
- Significance of PD-L1 Expression and Tumor Infiltrating Lymphocytes in High Grade Serous Ovarian Cancer: Egyptian Experience. January 2020, Indian Journal of Public Health.
- Dickkopf-1 and β-catenin as Biomarkers for Early Diagnosis of Hepatocellular Carcinoma. November 2019 Current Cancer Therapy Reviews.
- Slit2 low expression and promoter hypermethylation are associated with adverse outcome in diffuse large B. February 2019Pathology & Oncology Research.
- Single Nucleotide Polymorphism in Adiponectin Gene and Risk of Pancreatic Adenocarcinoma. January 2019 Asian Pacific Journal of Cancer Prevention.